Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Zhangzhou Pientzehuang Pharmaceutical., Ltd, together with its subsidiaries, manufactures and distributes pharmaceuticals and cosmetics in China and internationally. It offers Chinese medicines in various forms, including capsules, tablets, pills, syrups, and ointments, as well as health care food and functional drinks, special efficacy cosmetics, and household chemicals under the Pien Tze Huang … Read more
Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436) - Total Liabilities
Latest total liabilities as of September 2025: CN¥2.44 Billion CNY
Based on the latest financial reports, Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436) has total liabilities worth CN¥2.44 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zhangzhou Pientzehuang Pharmaceutical Co Ltd - Total Liabilities Trend (2000–2024)
This chart illustrates how Zhangzhou Pientzehuang Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Zhangzhou Pientzehuang Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhangzhou Pientzehuang Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Grupo Aeroportuario del Centro Norte SAB de CV
NASDAQ:OMAB
|
USA | $19.51 Billion |
|
International Games System Co Ltd
TWO:3293
|
Taiwan | NT$15.26 Billion |
|
Grifols S.A
PINK:GIFLF
|
USA | $12.17 Billion |
|
United Bankshares Inc
NASDAQ:UBSI
|
USA | $28.16 Billion |
|
DaVita HealthCare Partners Inc
NYSE:DVA
|
USA | $16.32 Billion |
|
Lithia Motors Inc
NYSE:LAD
|
USA | $18.48 Billion |
|
PNM Resources Inc
F:98P
|
Germany | €8.50 Billion |
|
CAR Group Ltd
AU:CAR
|
Australia | AU$1.89 Billion |
Liability Composition Analysis (2000–2024)
This chart breaks down Zhangzhou Pientzehuang Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhangzhou Pientzehuang Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhangzhou Pientzehuang Pharmaceutical Co Ltd (2000–2024)
The table below shows the annual total liabilities of Zhangzhou Pientzehuang Pharmaceutical Co Ltd from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.70 Billion | -14.53% |
| 2023-12-31 | CN¥3.16 Billion | +13.67% |
| 2022-12-31 | CN¥2.78 Billion | +17.86% |
| 2021-12-31 | CN¥2.36 Billion | +21.01% |
| 2020-12-31 | CN¥1.95 Billion | +5.86% |
| 2019-12-31 | CN¥1.84 Billion | +36.36% |
| 2018-12-31 | CN¥1.35 Billion | +10.39% |
| 2017-12-31 | CN¥1.22 Billion | -4.97% |
| 2016-12-31 | CN¥1.29 Billion | +71.24% |
| 2015-12-31 | CN¥751.60 Million | +13.48% |
| 2014-12-31 | CN¥662.34 Million | -0.71% |
| 2013-12-31 | CN¥667.05 Million | -1.21% |
| 2012-12-31 | CN¥675.22 Million | +77.83% |
| 2011-12-31 | CN¥379.69 Million | +4.61% |
| 2010-12-31 | CN¥362.97 Million | -15.07% |
| 2009-12-31 | CN¥427.35 Million | +34.20% |
| 2008-12-31 | CN¥318.45 Million | +50.19% |
| 2007-12-31 | CN¥212.03 Million | +93.59% |
| 2006-12-31 | CN¥109.53 Million | +28.01% |
| 2005-12-31 | CN¥85.56 Million | +334.47% |
| 2004-12-31 | CN¥19.69 Million | -52.44% |
| 2003-12-31 | CN¥41.40 Million | -75.79% |
| 2002-12-31 | CN¥170.99 Million | +37.51% |
| 2001-12-31 | CN¥124.34 Million | +5.98% |
| 2000-12-31 | CN¥117.33 Million | -- |